2026-08-13 | Does Crocus sativus (Saffron) Have an Influence or Effect on Ocular Health: A Systematic Literature Review.
BackgroundCrocus sativus (Saffron) and its bioactive constituents, crocin and crocetin have gained attention for their neuroprotective and antioxidant properties in ocular health. This review synthesises clinical evidence from extracted studies evaluating their efficacy, safety and dosing across Age-related Macular Degeneration (AMD), Primary Open-Angle Glaucoma (POAG), Diabetic Macular Edema (DME), Central Serous Retinopathy (CSR), Stargardt Disease (STGD1) and Paediatric Myopia (PM).MethodologyA systematic literature review was undertaken assessing randomized trials, observational or cohort studies, case studies or series written in English between January 2015 to January 2025. Studies were identified using PubMed, AMED, CINHAL, ScienceDirect and Scopus as well as the grey literature.ResultsTen clinical trials were identified from 529 citations. Interventions involved oral supplementation of saffron (20-50mg/day), crocin (5-15mg/day) and crocetin (7.5mg/day) over durations ranging from 6 weeks to 12 months. Primary outcomes included visual acuity, retinal electrophysiology, intra-ocular pressure, macular thickness, and safety profiles.ConclusionSaffron, crocin and crocetin, demonstrate consistent efficacy and exceptional safety profiles across a range of ocular conditions. Saffron's dose-dependent therapeutic effects are a promising adjunctive therapy in ophthalmology. Further large-scale trials are warranted to confirm these findings and refine condition specific dosing.
Open article ↗
2026-07-29 | V3-RGN-09 Molecular Simulator: A Formally Verified Ada/SPARK In Silico Engine for Dual-Target Retinal Regeneration and Biophysical Blind-Test Validation
BACKGROUND & PURPOSE: Retinal degenerative disorders—such as age-related macular degeneration (AMD), diabetic macular edema (DME), and glaucoma—represent complex multi-layered neuropathologies that remain challenging to model in silico without computational instability or artificial bias. Traditional computational biology frameworks (primarily C/C++ or Python) lack formal safety guarantees and deterministic physical boundaries. This work introduces the "V3-RGN-09 Molecular Simulator", an in silico biophysical platform developed entirely in Ada/SPARK 2022 to simulate the complete mechanics of multi-layered retinal regeneration and drug-target interactions with 100% formal mathematical proof (zero runtime exceptions, zero memory bugs). METHODOLOGY & ARCHITECTURE: The simulator relies on four locked V3 Invariants: 1. Physical Mass/Pressure Invariant (Ψ_V3 = 48,016.8 kg·m⁻²), 2. Critical Biophysical Phase Lock Attractor (Φ_critical = -51.10 mV vs. Φ_basal = -70.00 mV), 3. Heptadic Layer Closure (k = 7, modeling all 7 distinct anatomical retinal layers), 4. Modulo-9 Checksum Predicates guaranteeing structural integrity across all execution threads. The core module evaluates the novel synthetic hybrid molecule V3-RGN-09 (Molecular Weight: 842.6 Da, ΔG = -11.8 kcal/mol, Kd = 0.042 nM), engineered from 3D atomic coordinates of PDB 6M76 (TGFBR1 / Anti-TGF-β Domain A) and PDB 1BND (TrkB/PEDF Neurotrophic Domain B). EXPERIMENTAL VALIDATION & BLIND TESTS: The architecture underwent extensive stress-testing and empirical validation: 1. Blind Diagnostic Simulations (16/16 Successful): Without diagnostic tags or clinical labels, the engine evaluated raw physical parameters (fluid pressure, ion gradients, mechanical stress, enzymatic clearance). Through differential integration across the 7 layers (k=7), the engine autonomously rediscovered exact real-world pathological footprints, including Wet/Dry AMD, Glaucoma, Stargardt Disease, Central Retinal Artery Occlusion (CRAO), Macular Holes, and CAR Retinopathy with 100% concordance to clinical benchmarks. 2. Reverse Engineering / Back-Propagation Test: By setting an optimal clinical recovery target (Phase Lock at -51.10 mV in 18 days with >75% fibrosis reduction), back-propagation equations independently generated the precise structural and affinity constraints of the V3-RGN-09 hybrid pharmacophore. 3. Extreme Stress Testing & Fuzzing: Monte-Carlo simulations (100,000 runs under ±15% parameter noise) demonstrated a 99.98% convergence rate to the Φ_critical attractor. Simulated memory corruption and bit-flips triggered instantaneous execution isolation (0.00 ms crash rate) via SPARK pre/post-conditions. 4. Clinical Benchmark Cross-Validation: Predicted clinical outcomes (+16.4 ETDRS letters gain, 78% fibrosis reduction, 92% RPE preservation) were cross-validated against real-world trial datasets from ANCHOR (n=423) and MARINA (n=716). CONCLUSION: The V3-RGN-09 Molecular Simulator bridges high-integrity critical software engineering (DO-178C standards) with computational biophysics. It provides a proven, deterministic, and formally verified foundation for in silico drug discovery, ready for TRL 4 in vitro and in vivo translational research.
Open article ↗
2026-06-26 | Therapeutic Efficacy of Multi-Characteristic Opsin Gene Therapy in a Mouse Model of Stargardt Disease.
Optogenetic gene therapy-based treatment offers a unique approach to bypass dysfunctional or degenerated photoreceptors in retinal degenerative disorders. Ambient light-activatable multi-characteristic opsin (MCO) targeted to bipolar cells of the retina has demonstrated partial vision restoration in animal models of retinitis pigmentosa (RP). Here, we describe the potential therapeutic efficacy of intravitreally delivered AAV-carried MCO-010 in a mouse model of Stargardt disease. MCO-010 treatment led to significantly improved behavioral outcomes in the visually guided radial arm water maze. Furthermore, longitudinal optical coherence tomographic imaging showed that the MCO-010 treatment led to no notable change in the retina thickness. Furthermore, the MCO-010-treated mice exhibited higher electrophysiological responses compared to the control group. Together, these findings demonstrate potential vision-restoring and disease-modifying aspects of ambient light-activatable intravitreal MCO-010 therapy.
Open article ↗
2026-06-04 | Update on the Management of ABCA4 Retinopathy (Stargardt Disease).
ABCA4-associated retinopathies (Stargardt disease) are the most common inherited macular dystrophy and a leading cause of early onset central vision loss. Biallelic pathogenic variants in the ABCA4 gene cause impaired clearance of retinoid byproducts, leading to toxic bisretinoid accumulation, retinal pigment epithelium dysfunction, and progressive photoreceptor degeneration. Clinical presentation and disease progression are highly heterogeneous, largely influenced by genotype, age at onset, and environmental modifiers. Current management remains supportive and includes low-vision rehabilitation and counseling. Recent advances in molecular genetics, retinal imaging, and translational science have substantially expanded the therapeutic pipeline for ABCA4 retinopathy. Disease-modifying strategies under active investigation include visual-cycle modulation, deuterated vitamin A analogs, retinol-binding protein antagonists, gene augmentation and editing approaches, antisense oligonucleotides, and cell-based regenerative therapies. Several pharmacologic agents have demonstrated promising structural outcomes in clinical trials, while gene-based and regenerative approaches continue to evolve amid challenges related to gene size, delivery efficiency, and long-term safety. Optogenetic therapy has emerged as a gene-agnostic option for functional vision restoration in advanced disease stages. This review provides an integrated overview of ABCA4 retinopathy, summarizing disease mechanisms, current management strategies, emerging therapies, and the evolving clinical trial landscape. Emphasis is placed on stage-adapted treatment paradigms, appropriate monitoring endpoints, and the potential role of combination therapies. Ongoing innovation and precision-based approaches offer cautious optimism for durable disease modification and functional preservation in this currently untreatable condition.
Open article ↗
2026-06-02 | Exendin-4 averts all-trans-retinal-driven damage to photoreceptors and the retina via the GLP-1R/PKA/CREB1 signaling axis.
Atrophic macular degeneration comprises dry age-related macular degeneration (AMD) and autosomal recessive Stargardt disease (STGD1). These disorders lead to irreversible blindness and still lack effective therapies. The rise of all-trans-retinal (atRAL) brought on by visual cycle disruption closely links to retinal atrophy in both conditions, yet the key downstream targets remain obscure. Exendin-4 (EX-4) is a natural glucagon-like peptide-1 receptor (GLP-1R) agonist. Recent clinical retrospective studies indicate that GLP-1R agonists such as exenatide (synthetic EX-4) can markedly lower the 5-year risk of developing dry AMD. Here, we sought to clarify the protective effect of natural EX-4 against retinal degeneration in atrophic macular degeneration linked to impaired clearance of atRAL. Cell and animal paradigms of STGD1 and dry AMD were generated by atRAL-loaded 661W cells and light-exposed Abca4-/-Rdh8-/- mice, respectively. RNA-sequencing, cell viability assays, morphometric analysis, annexin V/propidium-iodide staining using flow cytometry, quantitative polymerase chain reaction (qPCR), western blotting, immunofluorescence, electroretinography (ERG), fundus photography, hematoxylin and eosin (H&E) histology, and TUNEL staining were integrated to delineate the anti-apoptotic actions of EX-4 and to uncover its underlying protective mechanism. GLP-1R/cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA)/cAMP response element-binding protein 1 (CREB1) signaling was markedly downregulated in atRAL-challenged 661W cells and in neural retina of light-exposed Abca4-/-Rdh8-/- mice. EX-4 reinstated this pathway, suppressed caspase-3 activation and DNA damage, and curtailed apoptosis in both cell and tissue contexts. Silencing of Glp1r or the PKA catalytic subunits by small interfering RNA (siRNA) abrogated EX-4-induced activation of the PKA/CREB1 axis in atRAL-loaded 661W cells. Pharmacologic blockade of CREB1 phosphorylation with the PKA inhibitor H-89 or the CREB1 inhibitor 666-15 largely nullified the DNA-protective and anti-apoptotic benefits conferred by EX-4 in 661W cells following atRAL exposure, suggesting that the GLP-1R/PKA/CREB1 signaling axis contributes to its cytoprotection action. More importantly, intraperitoneal injection of EX-4 significantly preserved retinal structure and function in Abca4-/-Rdh8-/- mice after exposure to light, and mitigated punctate lesions in the fundus. EX-4 exerted anti-apoptotic and DNA-protective effects against atRAL-induced photoreceptor loss and retinal degeneration at least partially through activating the GLP-1R/PKA/CREB1 pathway. These findings suggest that GLP-1R agonists could serve as potential preventive therapeutics for atrophic macular degeneration associated with atRAL toxicity, including dry AMD and STGD1.
Open article ↗
